{"id":"NCT02092350","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety and Efficacy of Grazoprevir (MK-5172) + Elbasvir (MK-8742) in Participants With Chronic Hepatitis C and Chronic Kidney Disease (MK-5172-052)","officialTitle":"A Phase II/III Randomized Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 and MK-8742 in Subjects With Chronic Hepatitis C Virus Infection and Chronic Kidney Disease","status":"COMPLETED","phase":"PHASE2","dates":{"start":"2014-03-17","primaryCompletion":"2015-03-11","completion":"2015-09-02","firstPosted":"2014-03-20","resultsPosted":"2016-04-12","lastUpdate":"2018-09-24"},"enrollment":237,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C Virus"],"interventions":[{"type":"DRUG","name":"Grazoprevir","otherNames":["MK-5172"]},{"type":"DRUG","name":"Elbasvir","otherNames":["MK-8742"]},{"type":"DRUG","name":"Placebo to Grazoprevir","otherNames":[]},{"type":"DRUG","name":"Placebo to Elbasvir","otherNames":[]}],"arms":[{"label":"Immediate Treatment","type":"EXPERIMENTAL"},{"label":"Deferred Treatment","type":"EXPERIMENTAL"},{"label":"Intensive PK","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the safety and efficacy of combination treatment with grazoprevir (MK-5172) + elbasvir (MK-8742) for cirrhotic and non-cirrhotic participants with chronic Genotype 1 (GT1) hepatitis C virus (HCV) infection and chronic kidney disease (CKD). The primary study hypothesis is that the proportion of HCV GT1-infected CKD participants within the Immediate Treatment and Intensive Pharmacokinetics (PK) groups achieving a sustained viral response 12 weeks after the end of all study treatment (SVR12) will be \\>45%.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response 12 Weeks After Completing Study Therapy (SVR12)","timeFrame":"Week 24 (Immediate Treatment + Intensive PK) or Week 40 (Deferred Treatment)","effectByArm":[{"arm":"Immediate Treatment + Intensive PK","deltaMin":99.1,"sd":null},{"arm":"Deferred Treatment","deltaMin":98,"sd":null}],"pValues":[{"comp":"OG000","p":"0.001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":11,"exclusionCount":14},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["26456905","28576451","37096802","30680407","29404492","28193518"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":30,"n":122},"commonTop":["Headache","Nausea","Fatigue","Dizziness","Diarrhoea"]}}